Vivesto AB (OTCPK:OASMY)

$ 0.0499 0 (0%) Market Cap: 8.95 Mil Enterprise Value: 3.84 Mil PE Ratio: 0 PB Ratio: 0.87 GF Score: 33/100

Q3 2022 Vivesto AB Earnings Call Transcript
Nov 17, 2022

$0.35

Earnings
Q2 2022 Vivesto AB Earnings Call Transcript
Aug 25, 2022

$0.1

Earnings
Q1 2022 Vivesto AB Earnings Call Transcript
May 25, 2022

$0.2253

Earnings
Q4 2021 Oasmia Pharmaceutical AB Earnings Call Transcript
Feb 24, 2022

$0.525

Earnings
Oasmia Pharmaceutical AB Online Presentation Transcript
Jan 19, 2022
Q3 2021 Oasmia Pharmaceutical AB Earnings Call Transcript
Nov 18, 2021

$0.7135

Earnings
Q2 2021 Oasmia Pharmaceutical AB Earnings Call Transcript
Aug 19, 2021

$0.92255

Earnings
Oasmia Pharmaceutical AB (publ) - Special Call Transcript
Mar 01, 2021
Full Year 2020 Oasmia Pharmaceutical AB Earnings Call Transcript
Feb 19, 2021

$1.1

Earnings
Q2 2021 Oasmia Pharmaceutical AB Earnings Call Transcript
Dec 09, 2020

$1.33

Earnings
LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript
Dec 03, 2020
Vivesto AB at Sachs Associates Biotech in Europe Forum (Virtual) Transcript
Sep 21, 2020
Q1 2021 Oasmia Pharmaceutical AB Earnings Call Transcript
Sep 09, 2020

$1.67

Earnings
Q4 2020 Oasmia Pharmaceutical AB Earnings Call Transcript
Jun 18, 2020

$1.9

Earnings

Vivesto AB at Sachs Associates Biotech in Europe Forum (Virtual) Transcript

Sep 21, 2020 - Sep 24, 2020 / NTS GMT

Release Date Price: $1.51 (-1.31%)

Transcript

Francois Martelet

Oasmia Pharmaceutical AB - CEO

Good morning, everyone. My name is Francois Martelet. I'm the CEO of Oasmia. Delighted to be here with you. I'm going to provide you an update on our company's business, Oasmia.

Oasmia is not, as you may expect, a drug delivery company, but we are an innovation focused, fully integrated specialty pharma company. We are using a technology platform in order to either reformulate existing compounds that are not water soluble or to create new compounds. And we have a portfolio in human health as well as in animal health. We have a lead product approved called Apealea, approved in Europe for advanced ovarian cancer. We have signed off a partnership with a US-based company.

We are listed on the Stockholm Stock Exchange with a market cap of around SEK2 billion. As I said earlier, we are really an R&D certified production facility and R&D lab testing integrated as well. I've been join the company in March of this year.

Building a sustainable, profitable specialty pharma company is our goal. And how do we do that?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.